| Richard F Mickevicius, MD | |
|
2251 N Shore Dr, Rhinelander, WI 54501-8360 | |
| (715) 361-2000 | |
| (715) 361-2877 |
| Full Name | Richard F Mickevicius |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 29 Years |
| Location | 2251 N Shore Dr, Rhinelander, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487749263 | NPI | - | NPPES |
| 32450500 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 40038 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension St Marys Hospital | Rhinelander, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aspirus Rhinelander And Tomahawk Hospitals And Clinics Inc | 9335059856 | 309 |
News Archive
VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
Medical researchers in the UK and Australia have identified a new marker which could support the search for novel preventative and therapeutic treatments for dementia.
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated.
› Verified 7 days ago
| Entity Name | Aspirus Rhinelander & Tomahawk Hospitals & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144991340 PECOS PAC ID: 9335059856 Enrollment ID: O20031126000706 |
News Archive
VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
Medical researchers in the UK and Australia have identified a new marker which could support the search for novel preventative and therapeutic treatments for dementia.
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard F Mickevicius, MD 2251 N Shore Dr, Rhinelander, WI 54501-8360 Ph: (715) 361-2000 | Richard F Mickevicius, MD 2251 N Shore Dr, Rhinelander, WI 54501-8360 Ph: (715) 361-2000 |
News Archive
VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
Medical researchers in the UK and Australia have identified a new marker which could support the search for novel preventative and therapeutic treatments for dementia.
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated.
› Verified 7 days ago
James V Grebner, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000 Fax: 715-361-2877 | |
Richard Mayrer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000 Fax: 715-361-2877 | |
Dr. Lynn P Gehrmann, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2100 | |
Peter J Zenti, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000 Fax: 715-361-2877 | |
Larry A Hooper, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000 Fax: 715-361-2877 | |
Scott L Marsan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000 Fax: 715-361-2877 |